Two University of Toledo scientists are exploring a new category of drug aimed at drug-resistant fungal infections, targeting the fungal genus Candida with support from the National Institutes of Health (NIH), the University of Toledo announced on November 18, 2026.
Dr. Heather Conti and Dr. Ronald Viola, of the College of Natural Sciences and Mathematics, are collaborating on the work, which is supported by more than $215,000 from the National Institute of Allergy and Infectious Diseases under a two-year grant, UToledo News reported.
Their approach uses covalent drugs, which work by binding irreversibly to a targeted molecule — in this case, an essential enzyme in Candida — instead of relying on the weaker, non-covalent bonds that other drug categories use to identify and inhibit a target, UToledo News reported…